Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The primary objectives in the dose escalation phase are to evaluate safety and
pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of
REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced
malignancies, including lymphoma.
The primary objectives in the dose expansion phase are to assess preliminary anti-tumor
activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as
measured by objective response rate (ORR).